Xiaojia Wang
Zhejiang Cancer Hospital(CN)First Affiliated Hospital of Henan University of Science and Technology(CN)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, Breast Cancer Treatment Studies, Estrogen and related hormone effects
Most-Cited Works
- → Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial(2021)378 cited
- → Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial(2019)264 cited
- → Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01(2024)110 cited
- → Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial(2019)87 cited
- → Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial(2023)79 cited
- →